Unique Alzheimer’s Disease Tau Vaccine Shows Great Potential in Pre-Clinical Studies
MultiTEP Platform-Based Epitope Vaccine Targeting the Phosphatase Activating Domain (PAD) of Tau Shows Clear Therapeutic Efficacy in PS19 Mice Capo…
Read more
TSI Reports Enrollment of First 10 Patients in its Phase 2 Ischemic Stroke Clinical Trial and Completion of its Phase 2 Study Protocol in Myocardial Infarction
Studies Aim to Confirm Safety and Efficacy of Novel Bio-inspired Clot-dissolving Therapy Thrombolytic Science, LLC (TSI) today announced progress with 10…
HIV vaccine nears clinical trial following new findings
A promising vaccine that clears an HIV-like virus from monkeys is closer to human testing after a new, weakened version…
Velabs to develop novel immune-based therapy for obesity
Announces strategic partnership with alytas therapeutics Velabs Therapeutics GmbH (Velabs), a biotech company focused on the rapid screening of functional…
IBD research smashes recruitment target two years early
by Anna Smith Cambridge University Hospital NHS Foundation Trust has announced that its inflammatory bowel disease (IBD) research has hit…
FDA Urges Inclusion Of Men In Breast Cancer Clinical Trials
Men with breast cancer have significantly fewer treatment options than women with the disease, partly due to exclusion from many…
FDA grants Fast Track designation for Farxiga in chronic kidney disease
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of…
Lilly’s case for Taltz helped by expanded approval
Eli Lilly on Monday won an expanded approval for its psoriasis and arthritis drug Taltz, securing a Food and Drug…
AstraZeneca’s Breztri scores in COPD trial, amping its case for triple-combo battle against GSK
AstraZeneca and GlaxoSmithKline have long locked horns in their battle for respiratory supremacy with the latter holding the clear advantage…
Spurned by FDA a decade ago, Kyowa Kirin wins nod for Parkinson’s drug
A 10-year wait obviously didn’t discourage Kyowa Kirin from changing the FDA’s mind for its add-on Parkinson’s disease therapy. Tuesday,…
